News >

Examining PD-L1 and TMB as Biomarkers of Immunotherapy Response in NSCLC

Caroline Seymour
Published: Thursday, Oct 17, 2019

James G. Herman, MD, director, Lung Cancer Program, professor of medicine, Department of Medicine, University of Pittsburgh

James G. Herman, MD

Ongoing research is examining how the biomarkers PD-L1 and tumor mutational burden (TMB) can be used in a complementary fashion to predict which patients with advanced non–small cell lung cancer (NSCLC) will benefit most from immunotherapy, said James G. Herman, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication